Current state of anticoagulants to treat deep venous thrombosis

Current Cardiology Reports

Volumn 16, Issue 3, 2014, Pages

  Vo, Timothy ^a   Vazquez, Sara ^b   Rondina, Matthew T ^c,d  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Apixaban; Dabigatran; Deep vein thrombosis; Edoxaban; Rivaroxaban; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; PLACEBO; RIVAROXABAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; BLEEDING; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT COMPLIANCE; PATIENT SELECTION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; MEDICATION COMPLIANCE; VEIN THROMBOSIS;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MEDICATION ADHERENCE; MORPHOLINES; PATIENT SELECTION; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; VENOUS THROMBOSIS;

EID: 84892700674     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0463-2     Document Type: Review

References (38)

1. Oger E. Incidence of venous thromboembolism: a communitybased study in Western France. EPI-GETBP study group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657-60.
2. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The worcester venous thromboembolism study: a populationbased study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722-7. doi:10.1111/j.1525-1497.2006.00458.x. (Pubitemid 43973557)
3. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4 -8. doi:10.1161/01.CIR.0000078468.11849.66.
4. Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost. 2011;106(3):405-15. doi:10.1160/TH11-02-0132.
5. Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28(4):465-76. doi:10.1007/s11239-009-0309- 3.
6. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Archives of internal medicine. 2004;164(1):17-26. doi:10.1001/archinte.164.1.17. (Pubitemid 38067385)
7. Vazquez SR, Freeman A, Van Woerkom RC, Rondina MT. Contemporary issues in the prevention and management of postthrombotic syndrome. Ann Pharmacother. 2009;43(11):1824-35. doi:10.1345/aph.1M185.
8. Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102(4):688-93. doi: 10.1160/TH09-04-0266.
9. Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly. Clinical and applied thrombosis/Hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2008;14(4):393 - 8. doi:10.1177/1076029608317942.
10. Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res. 2012;129(3):392-400. doi:10.1016/j.thromres.2011.12.014.
11. Brenner B, Hoffman R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood reviews. 2011;25(5):215-21. doi:10.1016/j.blre.2011.04.003.
12. Cohen AT, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost. 2012;107(6):1035-43. doi:10.1160/TH11-12-0859.
13. Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. European journal of internal medicine. 2012;23(8):692-5. doi:10.1016/j.ejim.2012.10.001.
14. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012;72(13):1739-53. doi:10.2165/11635730-000000000-00000.
15. .•• Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S-94S. doi:10.1378/chest.11-2301. These evidence-based guidelines discuss the treatment of DVT.
16. .•• Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016 - 23. doi:10.1182/blood-2011-10-378950. This outstanding review highlights patient characteristics important to consider when choosing between new or established anticoagulants.
17. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British journal of clinical pharmacology. 2010;70(5):703-12. doi:10.1111/j.1365-2125.2010.03753.x.
18. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. doi:10.1056/NEJMoa1007903.
19. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, RothW. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug metabolism and disposition: the biological fate of chemicals. 2008;36(2):386-99. doi:10.1124/dmd.107.019083. (Pubitemid 351185753)
20. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. doi:10.1056/NEJMoa0906598.
21. Schulman S, Kakkar AK, Schellong S, Goldhaber SZ, Henry E, Mismetti P et al., editors. A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). Presented at the 53rd Annual American Society of Hematology Meeting; 2011.
22. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-18. doi:10.1056/NEJMoa1113697.
23. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. doi:10.1056/NEJMoa1007432.
24. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013. doi:10.1056/NEJMoa1302507.
25. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699 - 708. doi:10.1056/NEJMoa1207541.
26. Raskob G, Buller H, Prins M, Segers A, ShiM, Schwocho L, et al. Edoxaban for the long-termtreatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. J Thromb Haemost. 2013;11(7):1287-94. doi:10.1111/jth.12230.
27. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263-71. doi:10.1160/TH10-05-0328.
28. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S-50S. doi:10.1378/chest.11-2298.
29. .• Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11(2):245-52. doi:10.1111/jth.12096. This review discussed important aspects of the laboratory assessment of novel oral anticoagulants.
30. .• Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87 Suppl 1:S141-5. doi:10.1002/ajh. 23202. This review discussed important aspects of the reversal of novel oral anticoagulants.
31. Nitzki-George D, Wozniak I, Caprini JA. Current state of knowledge on oral anticoagulant reversal using procoagulant factors. Ann Pharmacother. 2013;47(6):841-55. doi:10.1345/aph.1R724.
32. Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G, et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2013;11(1):177-9. doi:10.1111/jth.12038.
33. Cushman M. Treating acute venous thromboembolism: shift with care. NEJM. 2013. doi:10.1056/NEJMe1307413.
34. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86(1):452-63. (Pubitemid 32663974)
35. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Archives of internal medicine. 2004;164(20):2260-5. doi:10.1001/archinte.164.20.2260. (Pubitemid 39456437)
36. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost. 2006;32(7):651-8. doi:10.1055/s-2006-951293. (Pubitemid 44623373)
37. Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs & aging. 2006;23(8):651-71. (Pubitemid 44394947)
38. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979-87. doi:10.1111/j.1538-7836.2012.04866.x.